Immunotherapy – St. Bartholomew’s Hospital – Treatment Details

Survival:9.0 months
Toxicity Grade:2
Treatments:Immunotherapy
Drugs:Proleukin
Country:United Kingdom
City/State/Province:London
Hospital:St. Bartholomew’s Hospital
Journal:Link
Date:1/2001

 

Description:
Patients: This Phase II study involved 29 patients with malignant pleural mesothelioma. None of these patients had been administered previous chemotherapy or immunotherapy.

Treatment: The treatment consisted of the administration of human recombinant Interleukin-2.

Toxicity: Toxicities included fever (grade 2), cutaneous toxicity, nausea and vomiting (grade 1), and chest pains.

Results: Overall median survival was 9 months from the date of first treatment.

Support: The cost of the interleukin-2 was subsidized by Chiron UK Limited. Chiron manufactures interleukin-2 (Proleukin).

Correspondence: R.M. Rudd, MD

Get your free copy of
“Surviving Mesothelioma” Today!